



CNSX
PT

PACIFIC THERAPEUTICS LTD. ISSUES OPTIONS TO CONSULTANTS

VANCOUVER, BRITISH COLUMBIA- (March 14, 2012) – Pacific Therapeutics Ltd. (the “Issuer”) is a development stage specialty pharmaceutical company focused on the identification and development of drug candidates to treat diseases of excessive scarring (fibrosis).

The Issuer is pleased to announce that it has granted incentive stock options to certain consultants.

Subject to CNSX Exchange approval, the Issuer granted 100,000 options pursuant to the Issuers stock option plan. The options may be exercised up until March 1, 2014 at an exercise price of \$0.15.

ABOUT PACIFIC THERAPEUTICS LTD.

The Issuer’s strategy includes reformulating approved drugs to increase efficacy and patient compliance, completing the further clinical testing, manufacturing and other regulatory requirements sufficient to seek marketing authorizations. This strategy may reduce the risk, time and cost of developing therapies for fibrosis by avoiding the risks associated with basic research and using compounds with unknown safety and toxicity profiles. The company’s lead drug candidate is PTL-202 a combination of approved drugs focused on treating fibrosis such as Idiopathic Pulmonary Fibrosis.

On Behalf of the Board of Directors

/s/ Doug Unwin

Douglas H. Unwin, CEO & President
(604) 738-1049
unwin@pacifitherapeutics.com
www.pacifitherapeutics.com

The CNSX or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.

409 Granville Street Suite 1023, Vancouver, BC V6C 1T2
Ph: (604) 738-1049 Fax: (604) 738-1094